论文部分内容阅读
1949年,Meneghini证实静注疫苗能引起血栓的溶解;1955年,Tillet等首先将链激酶(SK)作静脉注射;1961年,Hansen等将尿激酶(UK)最早用于临床。此后,溶栓疗法有了不断发展,本文就此作一简述。溶栓制剂 SK是应用最普遍的溶栓剂,由β溶血性链球菌培养液分离而得。SK与纤溶酶原(PIg)形成1:1复合物,即100,000单位(u)的复合物是由200,000单位的SK与等量的PIg反应而成,但是复合物的抗原性与游离的SK相似。 UK是从尿液或肾组织培养液中分离所得,无抗原性,可直接激活PIg。UK的半衰期
In 1949, Meneghini confirmed that intravenous vaccination caused thrombolytic effects. In 1955, Tillet et al first injected streptokinase (SK) intravenously. In 1961, Hansen et al. First used urokinase (UK) in clinical practice. Since then, thrombolytic therapy has been the continuous development of this article to make a brief description. Thrombolytic preparation SK is the most commonly used thrombolytic agent, from the hemolytic streptococcus culture fluid derived. The formation of a 1: 1 complex of SK with plasminogen (PIg), ie, 100,000 units (u) of complex was made by reacting 200,000 units of SK with an equal amount of PIg, but the antigenicity of the complex was compared to the free SK similar. UK is isolated from urine or kidney tissue culture medium, non-antigenic, can be directly activated PIg. UK half-life